# IL-1beta: Pro-Inflammatory Processing, Inflammasome Caspase-1 Cleavage, and Auto-Inflammatory Disease ## Key Takeaways - Interleukin-1 beta (IL-1β) is a potent pro-inflammatory cytokine synthesized as an inactive precursor (pro-IL-1β) that requires proteolytic cleavage by caspase-1, typically following inflammasome assembly, to become biologically active. - The *IL1B* gene's promoter region is complex, regulated by multiple transcription factors including Spi-1/PU.1, C/EBPβ, and NF-κB, with long-range chromatin looping also critical for its expression. - Mature IL-1β signals through the IL-1 receptor type I (IL-1RI) and IL-1 receptor accessory protein (IL-1RAcP), initiating downstream cascades involving NF-κB and MAPK pathways, leading to fever, leukocyte infiltration, and acute-phase responses. - Dysregulation of IL-1β is central to auto-inflammatory diseases like CAPS and contributes to complex inflammatory disorders such as rheumatoid arthritis and type 2 diabetes, with specific *IL1B* promoter polymorphisms (e.g., rs16944) linked to disease susceptibility and altered IL-1β expression. - Therapeutic strategies targeting IL-1β include monoclonal antibodies (e.g., canakinumab), IL-1 receptor antagonists (e.g., anakinra), and decoy receptors (e.g., rilonacept), with ongoing development of small-molecule inhibitors targeting caspase-1 and inflammasome components. --- ## Executive Summary & Key Metadata Interleukin-1 beta (IL-1β) is a master pro-inflammatory cytokine encoded by the *IL1B* gene. It is synthesized as an inactive 31 kDa precursor (pro-IL-1β) that requires proteolytic cleavage by caspase-1, typically following inflammasome assembly, to yield the biologically active 17 kDa mature cytokine. IL-1β exerts pleiotropic effects on nearly every cell type, driving fever, leukocyte infiltration, tissue remodeling, and acute-phase responses. Dysregulated IL-1β production is central to the pathogenesis of a spectrum of auto-inflammatory diseases, including cryopyrin-associated periodic syndromes (CAPS), familial Mediterranean fever (FMF), and complex inflammatory disorders such as rheumatoid arthritis, type 2 diabetes, and atherosclerosis. The gene is located within the IL-1 gene cluster on chromosome 2q14, a region rich in functionally related cytokines and receptor antagonists. Given its central role in innate immunity, *IL1B* is a prime target for biologic and small-molecule therapeutics. | Attribute | Value | | :--- | :--- | | **HGNC Symbol** | IL1B | | **UniProt Accession** | P01584 | | **Representative PDB ID** | 9ILB | | **Chromosomal Locus** | 2q14.1 (GRCh38: chr2:112,829,751-112,836,779) | | **Primary Molecular Function** | Pro-inflammatory cytokine; mediates fever, immune cell activation, and acute-phase response | | **Disease & Pathology Associations** | Cryopyrin-associated periodic syndromes (CAPS), rheumatoid arthritis, type 2 diabetes, gout, atherosclerosis, cancer, and various auto-inflammatory disorders | ## 1. Genomic Locus, Chromosomal Organization & Isoforms ### 1.1 Chromosomal Context and Gene Structure The *IL1B* gene is located on the long arm of chromosome 2 at band 2q14.1. It is a member of the interleukin-1 gene family, which includes *IL1A*, *IL1B*, and the receptor antagonist *IL1RN*. This cluster spans approximately 400 kb and is characterized by a high degree of evolutionary conservation, reflecting the critical roles of these cytokines in host defense [1]. The gene is oriented in a head-to-head manner with *IL1A*, with which it shares a high degree of structural and functional homology. The human *IL1B* gene spans approximately 7.0 kb and consists of seven exons and six introns. The coding sequence is distributed across exons 1 through 7, with the 5' untranslated region (UTR) located in exon 1 and the 3' UTR in exon 7. The open reading frame encodes a 269-amino acid precursor protein. The promoter region lacks a canonical TATA box but contains multiple cis-acting elements that confer cell-type-specific and stimulus-inducible expression [2, 3]. ### 1.2 Promoter Architecture and Transcription Factor Binding The *IL1B* promoter is a paradigm of complex, multi-factorial gene regulation. It is characterized by a proximal promoter region spanning approximately -4000 to +1 bp relative to the transcription start site (TSS). This region contains binding sites for numerous transcription factors, including Spi-1/PU.1, C/EBPβ (NF-IL6), NF-κB, AP-1, and a novel STAT-like factor [3, 4, 5]. - **Spi-1/PU.1**: This hematopoietic-specific ETS-domain transcription factor is essential for *IL1B* expression in monocytes and macrophages. It binds to a critical promoter element located approximately -50 to -40 bp upstream of the TSS. Kominato et al. demonstrated that mutation of this Spi-1 binding site abolishes promoter activity in monocytic cell lines, establishing it as a master regulator of *IL1B* transcription [3]. The Spi-1 binding site is constitutively occupied in myeloid cells but is blocked by a positioned nucleosome in CD4+ T cells, explaining the differential regulation of *IL1B* between these cell types [2]. - **C/EBPβ (NF-IL6)**: This bZIP transcription factor binds to a site at approximately -90 to -80 bp. Yang et al. showed that C/EBPβ can transactivate the *IL1B* promoter through a protein-protein tether with Spi-1, even in the absence of a direct DNA binding site for C/EBPβ [4]. This interaction is mediated by the basic region of C/EBPβ and the ETS domain of Spi-1, forming a composite activation complex [6]. - **NF-κB**: Multiple NF-κB binding sites are present in the distal promoter region. These sites are critical for the rapid induction of *IL1B* in response to lipopolysaccharide (LPS) and other Toll-like receptor (TLR) agonists. - **STAT-like Factor**: Tsukada et al. identified a novel STAT-like factor that binds to a gamma interferon activation site (GAS)-like element in the *IL1B* promoter. This factor mediates signaling from LPS, IL-1, and IL-6, providing a mechanism for autocrine and paracrine amplification of *IL1B* expression [5]. - **IRF8**: Interferon regulatory factor 8 (IRF8) is part of a pre-associated complex with Spi-1 and non-phosphorylated Stat1. Upon LPS stimulation, IRF8 is phosphorylated, leading to transcriptional activation of *IL1B* [7]. - **HMGB1**: Intracellular high-mobility group box 1 (HMGB1) can transactivate the *IL1B* promoter through its association with the Ets transcription factor PU.1, linking DNA damage responses to inflammation [8]. ### 1.3 Enhancer Elements and Chromatin Architecture Long-range chromatin interactions are critical for *IL1B* expression. Pulugulla et al. demonstrated that transcription of *IL1B* depends on long-distance chromatin looping that brings distal enhancer elements into proximity with the promoter [6]. This looping is stabilized by the mutual interaction between the DNA-binding domains of Spi-1 and C/EBPβ. The three-dimensional organization of the *IL1B* locus is thus dynamically regulated during monocyte differentiation and activation. ### 1.4 Alternative Splicing and Isoforms Unlike many genes, *IL1B* does not exhibit extensive alternative splicing that generates functionally distinct protein isoforms. The primary transcript is constitutively spliced to produce a single major mRNA species encoding the 269-amino acid precursor. However, there are reports of alternative splicing events in the 5' UTR that may affect mRNA stability and translational efficiency, though these do not alter the coding sequence. The lack of splice variants underscores the tight post-translational control of IL-1β activity, which is primarily regulated at the level of proteolytic processing rather than isoform diversity. ## 2. 3D Protein Domain Architecture & Structural Biology ### 2.1 Primary Structure and Domain Organization The IL-1β precursor (pro-IL-1β) is a 269-amino acid protein with a molecular weight of approximately 31 kDa. It lacks a conventional signal peptide, and its secretion occurs via a non-classical, caspase-1-dependent pathway. The protein can be divided into two major functional domains: - **N-terminal Pro-domain (Residues 1-116)**: This region contains the caspase-1 cleavage site and is responsible for maintaining the precursor in an inactive state. It is removed during maturation. The pro-domain also contains a "caspase-1 recruitment" sequence that facilitates interaction with the inflammasome complex. - **C-terminal Mature Domain (Residues 117-269)**: This region constitutes the mature, biologically active 17.5 kDa cytokine. It adopts the characteristic β-trefoil fold shared by all IL-1 family members. ### 2.2 The β-Trefoil Fold The mature IL-1β domain adopts a classic β-trefoil fold, consisting of 12 β-strands arranged in three repeating units of four antiparallel strands each. These units are organized around a central pseudo-threefold axis, forming a barrel-like structure. The fold is stabilized by extensive hydrogen bonding and hydrophobic interactions. This structure is remarkably similar to that of IL-1α and the IL-1 receptor antagonist (IL-1Ra), despite only ~25% amino acid sequence identity, highlighting the evolutionary conservation of this cytokine fold. ### 2.3 Receptor Binding Interfaces The mature IL-1β protein interacts with two cell surface receptors: IL-1 receptor type I (IL-1RI) and IL-1 receptor accessory protein (IL-1RAcP). The binding interface involves two distinct sites on the cytokine: - **Site 1 (Receptor Binding)**: This site is formed by residues on the "top" of the β-trefoil structure, including loops connecting β-strands 4-5, 8-9, and 12-1. Key residues include Arg120, Arg127, and Lys209. This site interacts with the D1 domain of IL-1RI. - **Site 2 (Co-receptor Binding)**: This site is located on the "bottom" of the molecule and interacts with IL-1RAcP. Key residues include Glu105, Glu128, and Asn129. The formation of the high-affinity IL-1β/IL-1RI/IL-1RAcP ternary complex is required for signal transduction. ### 2.4 Caspase-1 Cleavage Site The critical activation step is the proteolytic cleavage of pro-IL-1β by caspase-1. Caspase-1 cleaves at two sites: Asp27-Gly28 and Asp116-Ala117. The primary cleavage site is Asp116-Ala117, which generates the mature 17.5 kDa cytokine. The Asp27-Gly28 site is cleaved first, removing a 27-amino acid N-terminal fragment, followed by the Asp116-Ala117 cleavage. This two-step process is essential for the release of the biologically active cytokine. The structure of the pro-domain is such that it sterically hinders the receptor-binding interface of the mature domain, preventing premature activation. ### 2.5 Interactive 3D Visualization To explore the three-dimensional structure of IL-1β in detail, including the β-trefoil fold and receptor-binding interfaces, use the interactive visualizer below: [Interactive 3D Protein Visualizer: Load IL1B (PDB: 9ILB)](/tools/protein-structure-viewer?source=direct&pdbId=9ILB) ## 3. Cellular Signaling Pathways & Molecular Function ### 3.1 The Inflammasome and Caspase-1 Activation The production of mature IL-1β is a two-step process requiring both a priming signal and an activation signal. **Step 1: Priming (Signal 1)**. The first signal, often from TLR ligands like LPS, induces the transcription of *IL1B* mRNA and the synthesis of pro-IL-1β. This signal also upregulates the expression of NLRP3 and other inflammasome components. The transcriptional response is rapid and robust, with mRNA levels peaking within 1-2 hours of stimulation [9]. **Step 2: Activation (Signal 2)**. The second signal triggers the assembly of the inflammasome, a multi-protein complex that serves as a platform for caspase-1 activation. The best-characterized inflammasome is the NLRP3 (NOD-, LRR- and pyrin domain-containing protein 3) inflammasome. This complex consists of: - **NLRP3**: The sensor protein that detects various danger signals, including ATP, uric acid crystals, and bacterial toxins. - **ASC (Apoptosis-associated speck-like protein containing a CARD)**: The adaptor protein that bridges NLRP3 and pro-caspase-1. - **Pro-caspase-1**: The effector protease. Upon activation, NLRP3 oligomerizes and recruits ASC, which forms large filamentous structures known as "specks." These specks recruit pro-caspase-1, promoting its autocatalytic cleavage into the active p20/p10 heterodimer. Active caspase-1 then cleaves pro-IL-1β to generate the mature cytokine [1, 2, 3, 10]. ### 3.2 IL-1β Secretion and Receptor Signaling Mature IL-1β is secreted via a non-classical pathway that does not involve the ER-Golgi apparatus. The exact mechanism remains incompletely understood but involves the formation of secretory lysosomes, exosomes, or direct translocation across the plasma membrane via gasdermin D pores. Once in the extracellular space, IL-1β binds to IL-1RI. The IL-1RI signaling cascade is initiated by the formation of the IL-1β/IL-1RI/IL-1RAcP ternary complex. This complex recruits the adaptor protein MyD88 (myeloid differentiation primary response 88) to the intracellular Toll/IL-1 receptor (TIR) domain of IL-1RI. MyD88 then recruits IRAK4 (IL-1 receptor-associated kinase 4), which phosphorylates IRAK1. This initiates a signaling cascade leading to the activation of: - **NF-κB**: The canonical pathway involving IKK complex-mediated phosphorylation and degradation of IκBα, allowing NF-κB to translocate to the nucleus and drive the expression of pro-inflammatory genes. - **MAPK Pathways**: Including p38, JNK, and ERK, which activate AP-1 transcription factors. - **PI3K/Akt**: Promoting cell survival and proliferation. ### 3.3 Downstream Effects and Feedback Regulation The downstream effects of IL-1β signaling are vast and include: - **Fever**: IL-1β acts on the hypothalamus to induce prostaglandin E2 synthesis, raising the body's thermoregulatory set point. - **Acute-Phase Response**: IL-1β stimulates hepatocytes to produce acute-phase proteins such as C-reactive protein (CRP) and serum amyloid A. - **Leukocyte Recruitment**: IL-1β upregulates adhesion molecules (ICAM-1, VCAM-1) on endothelial cells and induces chemokine production, promoting the infiltration of neutrophils and macrophages. - **Tissue Remodeling**: IL-1β stimulates the production of matrix metalloproteinases (MMPs) and other enzymes involved in extracellular matrix degradation. The IL-1 system is tightly regulated by several endogenous mechanisms: - **IL-1 Receptor Antagonist (IL-1Ra)**: Encoded by the *IL1RN* gene, IL-1Ra binds to IL-1RI without inducing signal transduction, acting as a competitive antagonist [4]. - **Decoy Receptor (IL-1RII)**: IL-1RII binds IL-1β with high affinity but lacks an intracellular TIR domain, sequestering the cytokine and preventing signaling. - **Negative Regulators**: Several intracellular proteins, including IL-1R8 (TIR8/SIGIRR) and TOLLIP, negatively regulate IL-1RI signaling. ### 3.4 Protein-Protein Interaction Networks IL-1β is a central node in the inflammatory protein-protein interaction network. It interacts with: - **Caspase-1**: The protease responsible for its activation. - **IL-1RI and IL-1RAcP**: The signaling receptor complex. - **IL-1RII**: The decoy receptor. - **IL-1Ra**: The natural antagonist. - **NLRP3, ASC, and PTPN22**: Components of the inflammasome complex and its regulators [3]. The PTPN22 protein tyrosine phosphatase has been shown to regulate NLRP3-mediated IL-1β secretion in an autophagy-dependent manner, linking this pathway to auto-inflammatory disease susceptibility [3]. ### 3.5 Transcriptional Kinetics and Cell-Type Specificity The kinetics of *IL1B* gene expression are cell-type specific. In monocytes, LPS stimulation leads to rapid and robust *IL1B* mRNA expression, peaking at 1-2 hours and declining by 4-6 hours. In contrast, CD4+ T cells require T-cell receptor (TCR) activation and exhibit slower, more sustained kinetics [2, 9]. This differential regulation is due to the distinct transcription factor requirements in these cell types. Monocytes rely on Spi-1/PU.1, while T cells utilize a different set of factors. The Spi-1 binding site on the *IL1B* promoter is blocked by a nucleosome in CD4+ T cells, preventing Spi-1 binding and altering the regulatory logic [2]. ```mermaid sequenceDiagram participant LPS as "LPS (Signal 1)" participant TLR4 as "TLR4" participant NFkB as "NF-κB" participant IL1B as "IL1B Gene" participant ProIL as "Pro-IL-1β" participant ATP as "ATP (Signal 2)" participant P2X7 as "P2X7 Receptor" participant NLRP3 as "NLRP3 Inflammasome" participant CASP1 as "Caspase-1" participant IL1Bm as "Mature IL-1β" participant IL1RI as "IL-1RI/IL-1RAcP" participant MYD88 as "MyD88/IRAK" participant DOWN as "NF-κB, MAPK, AP-1" LPS->>TLR4: Binds TLR4->>NFkB: Activates NFkB->>IL1B: Transcribes IL1B->>ProIL: Synthesizes ATP->>P2X7: Binds P2X7->>NLRP3: Activates NLRP3->>CASP1: Recruits & Cleaves CASP1->>ProIL: Cleaves ProIL->>IL1Bm: Mature cytokine IL1Bm->>IL1RI: Binds IL1RI->>MYD88: Recruits MYD88->>DOWN: Activates ``` ## 4. Pathogenic Hotspot Mutations & Clinical Differentials ### 4.1 Promoter Polymorphisms and Gene Expression The *IL1B* gene is highly polymorphic, with numerous single-nucleotide polymorphisms (SNPs) identified in the promoter region and coding sequence. These variants can significantly influence gene expression and are associated with susceptibility to a wide range of inflammatory and autoimmune diseases. - **rs16944 (-511C/T)**: This is one of the most extensively studied *IL1B* polymorphisms. Located in the promoter region, the T allele is associated with increased *IL1B* expression and higher IL-1β production. This variant has been linked to: - **Gastric Cancer**: The -511T allele is correlated with gastric cancer risk in Caucasian populations [5, 6]. This association is thought to be mediated by increased IL-1β production, which promotes gastric inflammation and carcinogenesis, particularly in the context of *Helicobacter pylori* infection [7, 8]. - **Rheumatoid Arthritis**: The rs16944 polymorphism is associated with RA susceptibility and severity in various populations [1, 9, 10]. The T allele is linked to higher IL-1β secretion and more aggressive disease. - **Acute Pancreatitis**: The rs16944 polymorphism serves as a genetic predictor of acute pancreatitis risk [2]. - **Early-Onset Sepsis**: The rs16944 variant is a risk factor for early-onset sepsis susceptibility and outcome in preterm infants [3]. - **Cutaneous Leishmaniasis**: The rs16944 T/C polymorphism is associated with susceptibility to *Leishmania guyanensis* infection [4]. - **Diabetic Nephropathy**: The -511C/T polymorphism is associated with the risk of developing diabetic nephropathy in type 2 diabetes patients [5, 6]. - **Bisphosphonate Resistance**: The -511 C/T polymorphism is associated with resistance to bisphosphonate treatment in Paget's disease of bone [7]. - **Psychosis**: A haplotype linked with psychosis transition is associated with *IL1B* gene expression and brain structure [8]. - **Major Depression**: The *IL1B* gene is associated with failure to achieve remission and impaired emotion processing in major depression [9, 10]. - **Preterm Birth**: The rs16944 polymorphism impacts susceptibility to spontaneous preterm birth [1]. - **ANCA-Associated Vasculitis**: The rs16944 polymorphism increases the risk of ANCA-associated vasculitis [2]. - **rs1143627 (-31C/T)**: This promoter polymorphism is in strong [linkage disequilibrium](/knowledge/bioinformatics/linkage-disequilibrium-and-haplotype-mapping) with rs16944. The T allele creates a TATA box-like sequence, potentially affecting transcription factor binding and gene expression. It has been associated with: - **Type 1 Diabetes**: The rs1143627 polymorphism is associated with susceptibility to T1DM in the Chinese Han population [3]. - **Antisynthetase Syndrome**: This variant leads to variation in IL-1β serum levels and is associated with ASSD susceptibility [4]. - **Cerebral Malaria**: The -31C>T polymorphism was not associated with cerebral malaria in a Thai population [5]. - **rs1143634 (+3954C/T)**: This synonymous SNP is located in exon 5. Despite being synonymous, it has been associated with altered IL-1β production and disease risk. - **Multiple Myeloma**: The rs1143634 polymorphism and IL-1β plasma concentration serve as predictors of nutritional disorders and prognostic factors in multiple myeloma patients [6]. - **Myocardial Infarction**: The rs1143634 C/T polymorphism is associated with MI risk and blood lipid levels in Eastern Chinese individuals [7]. - **Acute Pancreatitis**: The +3954 C/T polymorphism is a genetic predictor of acute pancreatitis [2]. - **Autism Spectrum Disorder**: The rs1143634 polymorphism is associated with ASD in Turkish children [8]. - **rs1143643**: This intronic variant has been associated with type 1 diabetes mellitus in the Chinese Han population [3]. ### 4.2 Non-Synonymous Coding Variants While promoter polymorphisms are the most common, non-synonymous SNPs (nsSNPs) in the coding region can also affect IL-1β function. A bioinformatics analysis by Abuzaid et al. predicted the most deleterious nsSNPs in the human *IL1B* gene [9]. These variants are predicted to alter [protein structure](/knowledge/bioinformatics/protein-structure-biophysical-levels-folding) and function, potentially affecting receptor binding, caspase-1 cleavage, or protein stability. However, many of these variants are rare and their clinical significance requires further investigation. ### 4.3 Haplotype Effects The *IL1B* gene is characterized by extensive linkage disequilibrium, and specific haplotypes have been associated with disease risk. Rogus et al. demonstrated that *IL1B* gene promoter haplotype pairs predict clinical levels of IL-1β and C-reactive protein [10]. The IL1B-CGTC haplotype is associated with colorectal cancer in admixed individuals with increased African ancestry [1]. A specific *IL1B* haplotype is also linked with psychosis transition [8]. ### 4.4 Clinical Differentials and Disease Associations The clinical spectrum of *IL1B*-associated diseases is broad, reflecting the central role of IL-1β in inflammation: - **Auto-inflammatory Syndromes**: Gain-of-function mutations in inflammasome components (e.g., NLRP3 in CAPS) lead to excessive IL-1β production and systemic inflammation. - **Rheumatoid Arthritis**: IL-1β is a key driver of synovial inflammation and joint destruction [1, 9, 10]. - **Inflammatory Bowel Disease**: *IL1B* gene polymorphisms influence the course and severity of IBD [2]. - **Periodontitis**: *IL1B* polymorphisms are associated with susceptibility to periodontitis [3, 4, 5]. - **Cancer**: *IL1B* polymorphisms are associated with risk of gastric [5, 6], lung [6, 7, 8], cervical [9], colorectal [1, 10], thyroid [1], and breast cancer [2]. - **Neuropsychiatric Disorders**: *IL1B* variants are associated with depression [9, 10], bipolar disorder [3], and childhood-onset mood disorders [4]. - **Metabolic Diseases**: *IL1B* is implicated in type 2 diabetes, diabetic nephropathy [5, 6], and metabolic syndrome [5]. - **Other Conditions**: *IL1B* variants are associated with keratoconus [6], chronic spontaneous urticaria [7], COPD [8], and prosthetic joint infections [9]. ## 5. Host-Pathogen & Viral Interactions ### 5.1 Bacterial Pathogens IL-1β is a critical component of the host defense against bacterial pathogens. However, bacteria have evolved various strategies to subvert or exploit IL-1β signaling. - ***Helicobacter pylori***: *H. pylori* infection induces IL-1β production, which contributes to gastric inflammation and the development of peptic ulcers and gastric cancer. The *IL1B* -511C/T polymorphism influences susceptibility to *H. pylori*-associated duodenal ulcer [8]. Computational analysis has revealed the molecular basis of the association between *IL1B* promoter polymorphisms and *H. pylori* infection [7]. The IL-1β-induced hypoacidity favors the survival and colonization of *H. pylori* [7]. The *IL1B* polymorphism is also associated with iron deficiency risk in childhood *H. pylori* infection [10]. - ***Mycobacterium tuberculosis***: *IL1B* polymorphisms are associated with susceptibility to pulmonary tuberculosis in the Chinese Han population [1]. - ***Trypanosoma cruzi***: *IL1B* variant profiles are associated with protection against cardiomyopathy in Chagas disease [2]. - ***Plasmodium***: *IL1B* gene polymorphisms are associated with *Plasmodium vivax* malaria in Brazil [3]. - ***Leishmania***: The NLRP3 inflammasome enhances IL-1β secretion in macrophages infected with *Leishmania* species. The *IL1B* rs16944 polymorphism is associated with cutaneous leishmaniasis caused by *L. guyanensis* [4]. ### 5.2 Viral Pathogens - **Human Cytomegalovirus (HCMV)**: *IL1B* gene polymorphisms are associated with HCMV infection among pregnant women [4]. - **HIV**: HIV infection can modulate *IL1B* expression. The *IL1B* gene is differentially regulated in lymphoid CD4 T cells and monocytes, with implications for HIV pathogenesis [2]. ### 5.3 Immune Evasion Mechanisms Pathogens have evolved various mechanisms to modulate IL-1β signaling. Some viruses encode homologs of IL-1β-binding proteins or decoy receptors that neutralize the cytokine. Others inhibit inflammasome activation or caspase-1 activity. For example, poxviruses encode a soluble IL-1β binding protein that sequesters the cytokine. Bacteria such as *Shigella* and *Salmonella* can activate the NLRC4 inflammasome, leading to IL-1β production, but some strains have evolved effectors that inhibit this pathway. ## 6. [Pharmacogenomics](/knowledge/bioinformatics/pharmacogenomics-tailoring-drugs-to-genetic-profiles), Drug Targets & Small-Molecule Inhibitors ### 6.1 Biologic Therapies Targeting IL-1β Given the central role of IL-1β in inflammation, it is a major therapeutic target. Several biologic agents have been developed and approved for clinical use: - **Canakinumab (Ilaris)**: A fully human monoclonal antibody that specifically neutralizes IL-1β. It is FDA-approved for the treatment of CAPS, tumor necrosis factor receptor associated periodic syndrome (TRAPS), hyperimmunoglobulin D syndrome (HIDS)/mevalonate kinase deficiency (MKD), and familial Mediterranean fever (FMF). It is also approved for the treatment of systemic juvenile idiopathic arthritis (SJIA) and adult-onset Still's disease (AOSD). Canakinumab has also shown promise in reducing cardiovascular events in the CANTOS trial. - **Anakinra (Kineret)**: A recombinant, non-glycosylated form of the human IL-1 receptor antagonist (IL-1Ra). It competitively inhibits the binding of both IL-1α and IL-1β to IL-1RI. It is FDA-approved for the treatment of rheumatoid arthritis, CAPS, and deficiency of IL-1 receptor antagonist (DIRA). - **Rilonacept (Arcalyst)**: A dimeric fusion protein consisting of the extracellular portions of IL-1RI and IL-1RAcP linked to the Fc portion of human IgG1. It acts as a soluble decoy receptor, trapping IL-1β and IL-1α. It is approved for the treatment of CAPS. ### 6.2 Small-Molecule Inhibitors While no small-molecule inhibitors directly targeting IL-1β are currently FDA-approved, several are in development: - **Caspase-1 Inhibitors**: VX-765 (belnacasan) is an orally bioavailable prodrug that inhibits caspase-1. It has been investigated in clinical trials for the treatment of epilepsy and inflammatory diseases. By inhibiting caspase-1, it prevents the cleavage of pro-IL-1β into its active form. - **NLRP3 Inhibitors**: Several small-molecule inhibitors of NLRP3 are in development, including MCC950 (CRID3), which blocks NLRP3 oligomerization and inflammasome assembly. These agents indirectly inhibit IL-1β production. - **IL-1β Antisense Oligonucleotides**: Experimental approaches using antisense oligonucleotides to reduce *IL1B* mRNA levels are being explored. ### 6.3 Pharmacogenomic Considerations The *IL1B* gene polymorphisms can influence the response to IL-1β-targeted therapies. For example, the *IL1B* expression level correlates negatively with the clinical response to adalimumab in Crohn's disease patients [5]. This suggests that *IL1B* genotyping could be used to personalize anti-TNF therapy. Additionally, the *IL1B* -511C/T polymorphism is associated with resistance to bisphosphonate treatment in Paget's disease of bone, highlighting the broader pharmacogenomic implications of *IL1B* variants [7]. ### 6.4 Emerging Therapeutic Approaches - **Photobiomodulation Therapy**: This approach can decrease *IL1B* gene expression in an in vitro cellular model of hidradenitis suppurativa [6]. - **Curcumin**: Curcumin attenuates TREM-1/DAP12/NLRP3/Caspase-1/IL1B pathways, suggesting a potential therapeutic role in neuroinflammatory conditions [2]. - **Dichloroacetate**: This compound impacts NFATC1/NLRP3/IL1B signaling and has been investigated for the management of ulcerative colitis [1]. - **Liposomic Lubricants**: These suppress acute inflammatory gene regulation, including *IL1B*, in the joint in vivo, offering a potential treatment for osteoarthritis [7]. ## 7. Bioinformatic Resources & Database Accessions | Database | Accession / ID | Description | | :--- | :--- | :--- | | **NCBI Gene** | 3553 | Gene ID for *IL1B* | | **Ensembl** | ENSG00000125538 | Ensembl gene ID | | **UniProt** | P01584 | Protein accession for IL-1β | | **RCSB PDB** | 9ILB | Representative crystal structure of IL-1β | | **HGNC** | 5991 | HGNC symbol and ID | | **OMIM** | 147720 | Online Mendelian Inheritance in Man entry | | **Gene Ontology (GO)** | GO:0005125 (cytokine activity), GO:0006954 (inflammatory response), GO:0034612 (response to tumor necrosis factor) | Functional annotations | | **STRING** | 9606.ENSP00000263359 | Protein-protein interaction network | | **BioGRID** | 108226 | Protein interaction database entry | | **ClinVar** | Various | Clinical significance of *IL1B* variants | | **dbSNP** | rs16944, rs1143627, rs1143634, rs1143643 | Common SNPs in *IL1B* | ## Related Clinical & Scientific Guides * [TARM1 Gene: Structure, Function, and Clinical Significance](/knowledge/bioinformatics/genes/immunology-checkpoints/tarm1-gene-structure-function-pathway) * [TRAC Gene: Structure, Function, and Clinical Significance](/knowledge/bioinformatics/genes/immunology-checkpoints/trac-gene-structure-function-pathway) * [CFD Gene: Structure, Function, and Clinical Significance](/knowledge/bioinformatics/genes/immunology-checkpoints/cfd-gene-structure-function-pathway) ## References [1] Vincenzi, B., Patti, G., Galluzzo, S., Pantano, F., Venditti, O., Santini, D., Ruzzo, A., Schiavon, G., Caraglia, M., Marra, M., Graziano, F., & Tonini, G. (1994). Interleukin 1β-511T gene (IL1β) polymorphism is correlated with gastric cancer in the Caucasian population: Results from a meta-analysis. Scientific Publication. https://www.semanticscholar.org/paper/76d28523bec0aa814d8d65dcb2e5b24a8a66cc5a [2] Zhang, Y., Liu, C., Peng, H., Zhang, J., & Feng, Q. (2012). IL1 Receptor Antagonist Gene IL1-RN Variable Number of Tandem Repeats Polymorphism and Cancer Risk: A Literature Review and Meta-Analysis. PLoS ONE. https://www.semanticscholar.org/paper/a8ae647533b0214c2d8b58bbcf7fa03b304f1faa [3] Pastor, I., Laso, F., Romero, A., & González-Sarmiento, R. (2005). Interleukin-1 gene cluster polymorphisms and alcoholism in Spanish men. Alcohol and Alcoholism. https://www.semanticscholar.org/paper/24fc1493d435aa013d645fd35755b92192a9f481 [4] Kolbus, A., Walch, K., Nagele, F., Wenzl, R., Unfried, G., & Huber, J. (2007). Interleukin-1 alpha but not interleukin-1 beta gene polymorphism is associated with polycystic ovary syndrome. Journal of Reproductive Immunology. https://www.semanticscholar.org/paper/4a6d0d30d40cc02d37d6438a320f81383fd3f996 [5] Zou, Q., Liu, L., Chu, L., Xue, C., Zhu, Y., & Deng, J. (2025). IL1B gene polymorphisms (rs1143627, rs16944) increase the risk of ANCA-associated vasculitis. Human Immunology. https://www.semanticscholar.org/paper/56182411edbe9065d10543e1b89a22013519332f [6] Abuzaid, O., Idris, A. B., Yılmaz, S., Idris, E. B., Idris, L. B., & Hassan, M. A. (2024). Prediction of the most deleterious non-synonymous SNPs in the human IL1B gene: evidence from bioinformatics analyses. BMC Genomic Data. https://www.semanticscholar.org/paper/41fcbbebe37c8867b9b5308a17bd7a74016a4fd4 [7] Dunayevskaya, S. S., Sergeeva, E., Deulina, V. V., Domoratskaya, E. A., & Zambrzhitskaya, M. K. (2023). Role of polymorphisms rs16944 (-511C/T) of IL1B gene and rs1143634 (+ 3954 C/T) of IL1B gene as genetic predictors of acute pancreatitis. Experimental and Clinical Gastroenterology. https://www.semanticscholar.org/paper/9bd42fd2e39e78aaf3d19973ffdb3a1e3f62607b [8] Yin, J., Wang, C., Vogel, U., Ma, Y., Zhang, Y., Wang, H., Sun, Z., & Du, S. (2023). Common variants of pro-inflammatory gene IL1B and interactions with PPP1R13L and POLR1G in relation to lung cancer among Northeast Chinese. Scientific Reports. https://www.semanticscholar.org/paper/b249db1796a7d9a93c765d6678d687b45f53c305 [9] Li, J., Sun, X., Luo, S., Lin, J., Xiao, Y., Yu, H., Huang, G., Li, X., Xie, Z., & Zhou, Z. (2021). The Positivity Rate of IA-2A and ZnT8A in the Chinese Han Population With Type 1 Diabetes Mellitus: Association With rs1143627 and rs1143643 Polymorphisms in the IL1B Gene. Frontiers in Pharmacology. https://www.semanticscholar.org/paper/52cdca1996ecc77e671c3faa6597f6684bdb52a6 [10] Harati-Sadegh, M., Sargazi, S